1 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Tropical Medicine and International Health, Berlin, Germany.
2 Authors contributed equally.
3 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charité Comprehensive Cancer Center, Berlin, Germany.
4 Division of Clinical Tropical Medicine, Center of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.
5 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Medical Directorate, Berlin, Germany.
6 Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology, Berlin, Germany.
7 German Centre for Infection Research (DZIF), partner site Charité, Berlin, Germany.
8 Centre for Pathogen Evolution, Dept of Zoology, University of Cambridge, Cambridge, UK.
9 Labor Berlin - Charité Vivantes GmbH, Berlin, Germany.
10 Foundation for Innovative New Diagnostics, Geneva, Switzerland.
11 German Centre for Infection Research (DZIF), partner site Heidelberg, Heidelberg, Germany.
Professional nasal sampling is a reliable alternative to nasopharyngeal sampling when using a WHO-listed SARS-CoV-2 antigen-detecting rapid test. This less invasive method needs less training to facilitate rapid scaling of testing strategies.https://bit.ly/3pEVlUL